Cenk Tek1, Laura B Palmese2, Andrew D Krystal3, Vinod H Srihari2, Pamela C DeGeorge4, Erin L Reutenauer2, Sinan Guloksuz2. 1. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. Electronic address: cenk.tek@yale.edu. 2. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 3. Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA. 4. Department of Anesthesiology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Abstract
BACKGROUND: Insomnia is frequent in schizophrenia and may contribute to cognitive impairment as well as overuse of weight inducing sedative antipsychotics. We investigated the effects of eszopiclone on sleep and cognition for patients with schizophrenia-related insomnia in a double-blindplacebo controlled study, followed by a two-week, single-blind placebo phase. METHODS:Thirty-nine clinically stable outpatients with schizophrenia or schizoaffective disorder and insomnia were randomized to either 3mg eszopiclone (n=20) or placebo (n=19). Primary outcome measure was change in Insomnia Severity Index (ISI) over 8 weeks. Secondary outcome measure was change in MATRICS Consensus Cognitive Battery (MATRICS). Sleep diaries, psychiatric symptoms, and quality of life were also monitored. RESULTS:ISI significantly improved more in eszopiclone (mean=-10.7, 95% CI=-13.2; -8.2) than in placebo (mean=-6.9, 95% CI=-9.5; -4.3) with a between-group difference of -3.8 (95% CI=-7.5; -0.2). MATRICS score change did not differ between groups. On further analysis there was a significant improvement in the working memory test, letter-number span component of MATRICS (mean=9.8±9.2, z=-2.00, p=0.045) only for subjects with schizophrenia on eszopiclone. There were improvements in sleep diary items in both groups with no between-group differences. Psychiatric symptoms remained stable. Discontinuation rates were similar. Sleep remained improved during single-blind placebo phase after eszopiclone was stopped, but the working memory improvement in patients with schizophrenia was not durable. CONCLUSIONS:Eszopiclone stands as a safe and effective alternative for the treatment of insomnia in patients with schizophrenia. Its effects on cognition require further study.
RCT Entities:
BACKGROUND:Insomnia is frequent in schizophrenia and may contribute to cognitive impairment as well as overuse of weight inducing sedative antipsychotics. We investigated the effects of eszopiclone on sleep and cognition for patients with schizophrenia-related insomnia in a double-blind placebo controlled study, followed by a two-week, single-blind placebo phase. METHODS: Thirty-nine clinically stable outpatients with schizophrenia or schizoaffective disorder and insomnia were randomized to either 3mg eszopiclone (n=20) or placebo (n=19). Primary outcome measure was change in Insomnia Severity Index (ISI) over 8 weeks. Secondary outcome measure was change in MATRICS Consensus Cognitive Battery (MATRICS). Sleep diaries, psychiatric symptoms, and quality of life were also monitored. RESULTS: ISI significantly improved more in eszopiclone (mean=-10.7, 95% CI=-13.2; -8.2) than in placebo (mean=-6.9, 95% CI=-9.5; -4.3) with a between-group difference of -3.8 (95% CI=-7.5; -0.2). MATRICS score change did not differ between groups. On further analysis there was a significant improvement in the working memory test, letter-number span component of MATRICS (mean=9.8±9.2, z=-2.00, p=0.045) only for subjects with schizophrenia on eszopiclone. There were improvements in sleep diary items in both groups with no between-group differences. Psychiatric symptoms remained stable. Discontinuation rates were similar. Sleep remained improved during single-blind placebo phase after eszopiclone was stopped, but the working memory improvement in patients with schizophrenia was not durable. CONCLUSIONS:Eszopiclone stands as a safe and effective alternative for the treatment of insomnia in patients with schizophrenia. Its effects on cognition require further study.
Authors: Laura B Palmese; Pamela C DeGeorge; Joseph C Ratliff; Vinod H Srihari; Bruce E Wexler; Andrew D Krystal; Cenk Tek Journal: Schizophr Res Date: 2011-12 Impact factor: 4.939
Authors: Dara S Manoach; Matthew S Cain; Mark G Vangel; Anjali Khurana; Donald C Goff; Robert Stickgold Journal: Biol Psychiatry Date: 2004-12-15 Impact factor: 13.382
Authors: David A Lewis; Raymond Y Cho; Cameron S Carter; Kevin Eklund; Sarah Forster; Mary Ann Kelly; Debra Montrose Journal: Am J Psychiatry Date: 2008-10-15 Impact factor: 18.112
Authors: Elizabeth A Klingaman; Jessica Palmer-Bacon; Melanie E Bennett; Laura M Rowland Journal: Curr Psychiatry Rep Date: 2015-10 Impact factor: 5.285
Authors: Ellen E Lee; Sonia Ancoli-Israel; Lisa T Eyler; Xin M Tu; Barton W Palmer; Michael R Irwin; Dilip V Jeste Journal: Am J Geriatr Psychiatry Date: 2018-10-11 Impact factor: 4.105
Authors: Vincent F Capaldi; Jessica R Kim; Antigone A Grillakis; Maura R Taylor; Carla M York Journal: Curr Psychiatry Rep Date: 2015-10 Impact factor: 5.285